Related Experiment Video
Updated: Jul 4, 2025
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic Cardiomyopathy
Rebecca Haraf1, Hany Habib1, Ahmad Masri1
1The Hypertrophic Cardiomyopathy Center, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, USA.
Insights
Cardiac myosin inhibitors (CMIs) offer a new targeted therapy for hypertrophic cardiomyopathy (HCM), a common genetic heart condition. Clinical trials show CMIs effectively treat obstructive HCM, heralding a new era in patient management.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Pharmacology
Background:
- Hypertrophic cardiomyopathy (HCM) is a prevalent genetic heart disease with limited treatment options.
- Pathophysiology involves cardiac myosin hypercontractility, leading to significant morbidity and mortality.
Purpose of the Study:
- To review the discovery and development of cardiac myosin inhibitors (CMIs) for HCM.
- To summarize clinical trial results and provide guidance for CMI implementation.
- To identify research gaps and future directions in HCM management.
Main Methods:
- Review of scientific literature on HCM genetics and pathophysiology.
- Analysis of clinical trial data for CMIs in obstructive and nonobstructive HCM.
- Synthesis of information for clinical practice guidelines and future research.
Main Results:
- CMIs represent a novel class of drugs targeting HCM's underlying mechanism.
- Clinical trials demonstrate efficacy and safety of CMIs in patients with obstructive HCM.
- Ongoing trials explore CMI use in nonobstructive HCM, showing promising results.
Conclusions:
- CMIs offer a targeted, effective treatment strategy for HCM.
- The development of CMIs marks a significant advancement in managing this genetic cardiomyopathy.
- Further research will refine CMI application and expand treatment options for all HCM patients.
Abstract:
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy worldwide and causes significant morbidity and mortality. For decades, medical treatment options have been limited and untargeted, with frequent need for invasive interventions not readily accessible to many HCM patients. More recently, our understanding of the genetic basis and pathophysiologic mechanism of HCM has grown significantly, leading to the discovery of a new class of medications, cardiac myosin inhibitors (CMIs), that shift myosin into the super-relaxed state to counteract the hypercontractility in HCM. Subsequent clinical trials have proven the mechanism and efficacy of CMIs in humans with obstructive HCM, and additional trials are under way in patients with nonobstructive HCM. With favourable results in the completed clinical trials and ongoing research on the horizon, CMIs represent a bright new era in the targeted management of HCM. This review is focused on the discovery of CMIs, provides a summary of the results of clinical trials to date, provides clinicians with a roadmap for implementing CMIs into practice, and identifies gaps in our current understanding as well as areas of ongoing investigation.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...